Golimumab biosimilar is under clinical development by Alvotech and currently in Phase III for Rheumatoid Arthritis. According to GlobalData, Phase III drugs for Rheumatoid Arthritis have a 62% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Golimumab biosimilar’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Golimumab biosimilar overview
Monoclonal antibody is under development for the treatment of inflammation, rheumatoid arthritis and musculoskeletal diseases. The drug candidate is a biosimilar. It is developed based on SmartFactory GMP manufacturing platform. It is administered through subcutaneous and intravenous route.
Alvotech is a biopharmaceutical company that focused on development and manufacturing of biosimilar medicines. The company’s purpose is to improve the health and quality of life of patients by improving access to proven treatments for various diseases. Its current pipeline contains eight biosimilar candidates for the treatment of autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer, among others. It also offer research and development services. Alvotech work in partnerships and collaborations with other pharmaceutical companies and research universities which offering manufacturing, regulatory management and license agreements for its biosimilar assets. It has operations in Luxemburg, Switzerland, Germany and Iceland. Alvotech is headquartered in Luxemburg.
For a complete picture of Golimumab biosimilar’s drug-specific PTSR and LoA scores, buy the report here.